Next 10 |
2024-05-14 13:40:03 ET Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Conference Call May 14, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President and Chief Executive Officer Elliot Maltz - Chief Financial Officer ...
2024-05-14 07:34:18 ET More on Alimera Sciences Seeking Alpha’s Quant Rating on Alimera Sciences Historical earnings data for Alimera Sciences Financial information for Alimera Sciences Read the full article on Seeking Alpha For further details...
Net Revenue up 70% to $23 Million vs. Q1 2023 Global End User Demand Up 23% vs. Q1 2023 Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global p...
2024-05-13 13:39:39 ET More on Alimera Sciences Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Alimera Sciences Historical earnings data for Alimera Sciences Financial information for Alimera Sciences ...
ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today it ...
ATLANTA, April 30, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will repo...
2024-03-20 11:40:23 ET More on iShares Russell 1000 Growth ETF, iShares Russell 2000 ETF, etc. IWF ETF: Solid Track Record, But Looks Overextended Now IWM: Are Small Caps Being Overlooked In The Megacap Market Frenzy? IWM: Super Micro Computer Is Leading The Russell ...
ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better...
ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that th...
2024-03-07 12:52:07 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alimera Sciences (NASDAQ: ALIM ) just reported results for the fourth quarter of 2023. Alimera Sciences reported earnings per share of -7 cents. The company reported r...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
Alimera Sciences (NASDAQ: ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This comp...
Net Revenue up 70% to $23 Million vs. Q1 2023 Global End User Demand Up 23% vs. Q1 2023 Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global p...
ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today it ...